Sanofi-aventis and JDRF Form Partnership to Improve Therapies
- Details
- Category: Sanofi
Sanofi-aventis (EURONEXT: SAN and NYSE: SNY ) and the Juvenile Diabetes Research Foundation (JDRF) announced a unique partnership to develop therapeutic treatments for people with type 1 diabetes at different stages of the disease - both those living with the disease and the newly diagnosed - as well as preventing diabetes in those at risk.
Phase III study shows Novartis drug Afinitor® more than doubles time without tumor growth
- Details
- Category: Novartis
Novartis announced that results of a Phase III study show Afinitor® (everolimus) tablets plus best supportive care (BSC) more than doubled progression-free survival, or time without tumor growth, versus placebo plus BSC in patients with advanced pancreatic neuroendocrine tumors (NET).
Shire Purchases Strategic Site in Massachusetts
- Details
- Category: Shire
Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced its purchase of the Lexington Technology Park campus in Lexington, Massachusetts.
Single Treatment with ELONVA® Produced Live Birth Rates Comparable to Daily rFSH Injections
- Details
- Category: Merck
MSD announced findings from a follow-up study to the pivotal Engage Phase III trial. Treatment with a single corifollitropin alfa injection had comparable live birth rates with daily recombinant follicle stimulating hormone (rFSH) injections for the first week of stimulation.
AstraZeneca and MMV Join Efforts in the Fight Against Malaria
- Details
- Category: AstraZeneca
AstraZeneca and Medicines for Malaria Venture (MMV) announced a collaborative agreement designed to identify novel candidate drugs for the treatment of malaria. The agreement will initially allow MMV access to AstraZeneca's extensive compound library. MMV will seek to identify promising compounds with the potential to treat malaria, including drug resistant strains of the disease.
Victoza® (liraglutide) provided superior and sustained blood sugar control and weight reduction
- Details
- Category: Novo Nordisk
Late-breaking Novo Nordisk extension data presented at the 70th Annual Scientific Sessions of the American Diabetes Association (ADA) showed that once-daily Victoza® in combination with metformin produced sustained and significantly greater reductions in A1c, body weight and fasting plasma glucose (FPG) than Januvia® plus metformin at 52 weeks.
ONGLYZA (saxagliptin) with Metformin as Initial Combination Therapy
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN) announced results up to 76-weeks from a Phase 3 study of ONGLYZA™ (saxagliptin) as initial combination therapy with metformin, which produced long-term glycemic improvement [as measured by glycosylated hemoglobin level (HbA1c)] in treatment-naïve adults with type 2 diabetes mellitus inadequately controlled on diet and exercise compared to treatment with an investigational 10 mg dose of saxagliptin or metformin alone.
More Pharma News ...
- Pfizer Suspends Tanezumab Osteoarthritis Clinical Trial Program
- AstraZeneca and Targacept Initiate Phase 3 Clinical Development of TC-5214
- 34 Teachers and Schools Across North America Receive $10,000 Amgen Award
- New SIMPONI (Golimumab) Data Shows Sustained Efficacy in the Treatment of Rheumatoid Arthritis
- FDA approves Tasigna® for newly diagnosed chronic myeloid leukemia patients
- RoACTEMRA: New hope for children with systemic Juvenile Idiopathic Arthritis
- Bayer Schering Pharma and OncoMed Pharmaceuticals Enter Strategic Alliance